CORDIS
EU research results

CORDIS

English EN

Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases

Project information

Grant agreement ID: 853981

Status

Ongoing project

  • Start date

    1 November 2019

  • End date

    30 April 2025

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 40 922 058,50

  • EU contribution

    € 20 997 522,50

Coordinated by:

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

Project description

English EN

Identifying digital endpoints for fatigue and sleep

Patients with neurodegenerative disorders (NDD) and immune-mediated inflammatory diseases (IMID) are often affected by fatigue and sleep disturbances. These two disabling symptoms lead to poor quality of life and high healthcare costs. However, existing approaches to evaluate them are based on questionnaire methodology and have significant limitations. As a consequence, they are not reliable and do not take the impact of therapies into consideration. The EU-funded IDEA-FAST project will identify new digital endpoints for fatigue and sleep disturbances and offer a more objective and reliable evaluation of the seriousness and the effects of the symptoms. The purpose of the project is to understand the key mechanisms of these two disturbances and improve clinical trials envisaging new therapies with lower costs.

Coordinator

UNIVERSITY OF NEWCASTLE UPON TYNE

Address

Kings Gate
Ne1 7ru Newcastle Upon Tyne

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 6 226 301,75

Participants (45)

UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN

Germany

EU Contribution

€ 2 247 065

UNIVERSITA DEGLI STUDI DI BRESCIA

Italy

EU Contribution

€ 344 500

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 439 500

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 314 000

UNIVERSITY OF LIMERICK

Ireland

EU Contribution

€ 352 225

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

France

EU Contribution

€ 707 182

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 304 000

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 2 345 530

BYTEFLIES

Belgium

EU Contribution

€ 199 915

DREEM

France

EU Contribution

€ 195 250

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 720 165

LIXOFT SAS

France

EU Contribution

€ 499 937,50

ASOCIACION PARKINSON MADRID

Spain

EU Contribution

€ 250 000

STICHTING MLC FOUNDATION

Netherlands

EU Contribution

€ 500 000

TMF - TECHNOLOGIE UND METHODENPLATTFORM FUR DIE VERNETZTE MEDIZINISCHE FORSCHUNG EV

Germany

EU Contribution

€ 460 000

MEDIBIOSENSE LTD

United Kingdom

EU Contribution

€ 87 735

EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH

Germany

EU Contribution

€ 473 750

FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS

Portugal

EU Contribution

€ 280 000

PLURIBUS ONE SRL

Italy

EU Contribution

€ 287 500

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugal

EU Contribution

€ 289 500

Teknologian tutkimuskeskus VTT Oy

Finland

EU Contribution

€ 575 141,25

CAMBRIDGE COGNITION LIMITED

United Kingdom

EU Contribution

€ 150 000

UNIVERSIDAD AUTONOMA DE MADRID

Spain

EU Contribution

€ 230 000

ECOLE NATIONALE SUPERIEURE DES MINES DE DOUAI

France

EU Contribution

€ 326 750

MCROBERTS BV

Netherlands

EU Contribution

€ 147 750

GEORGE-HUNTINGTON-INSTITUT GMBH

Germany

EU Contribution

€ 358 950

INSTYTUT PSYCHIATRII I NEUROLOGII

Poland

EU Contribution

€ 170 000

MEDIZINISCHE UNIVERSITAT INNSBRUCK

Austria

EU Contribution

€ 353 125

HELSE STAVANGER HF

Norway

EU Contribution

€ 244 500

IXSCIENT LIMITED

United Kingdom

EU Contribution

€ 400 750

EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS

Belgium

EU Contribution

€ 35 000

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 134 500

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 347 000

JANSSEN PHARMACEUTICA NV

Belgium

TAKEDA DEVELOPMENT CENTRE EUROPE LTD

United Kingdom

ABBVIE INC

United States

ASTRAZENECA AB

Sweden

Eli Lilly and Company Limited

United Kingdom

PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG

United Kingdom

PFIZER LIMITED

United Kingdom

F. HOFFMANN-LA ROCHE AG

Switzerland

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

UCB BIOPHARMA SRL

Belgium

BIOGEN IDEC LIMITED

United Kingdom

ORION OYJ

Finland

Project information

Grant agreement ID: 853981

Status

Ongoing project

  • Start date

    1 November 2019

  • End date

    30 April 2025

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 40 922 058,50

  • EU contribution

    € 20 997 522,50

Coordinated by:

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom